Metsera | search
Click here to view Metsera news from 60+ newspapers.
Bookmark or Share- Metsera Reports Highly Competitive Results from Ongoing Trial of Novel ...NEW YORK, September 24, 2024 -- (BUSINESS WIRE)--Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today...
- Metsera GLP-1 data slice reveals 7.5% weight loss at 36 daysRecently debuted Metsera is unfolding some phase 1 data for its GLP-1 receptor agonist, revealing a 7.5% reduction in body weight compared to baseline at 36 days. While the biotech has yet to...
- Arch-backed obesity biotech launches with $290M - Fierce BiotechClinical-stage Metsera has emerged from stealth with $290 million in hand and the bold vision of ushering in the next generation of obesity and metabolic disease medicines. “It's an almost...
- MetseraMetsera is a clinical-stage biopharmaceutical company dedicated to leading the next generation of medicines and solutions for obesity and metabolic diseases.
- Metsera Launches to Lead the Next Generation of Medicines for Obesity ...NEW YORK, April 18, 2024 -- (BUSINESS WIRE)--Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases,...
More
